Simon Tate
About Simon Tate
Simon Tate's Professional Background
Simon Tate has amassed 30 years of experience in the field of research and development, particularly in the areas of Pain and Neuroscience. His extensive career includes significant roles at notable pharmaceutical companies such as GlaxoSmithKline (GSK) and Convergence Pharmaceuticals.
Education and Early Career of Simon Tate
Simon Tate originally trained as a biochemist and graduated from the University of Dundee. During his academic career, he had the opportunity to work with Sir Philip Cohen, who was recognized as the world's third most cited professor at the time.
Founding and Leading Convergence Pharmaceuticals
Simon Tate was one of the founders of Convergence Pharmaceuticals. As the Chief Scientific Officer and head of R&D, he played a pivotal role in steering the company towards a successful acquisition by Biogen for $675 million in 2015. His leadership significantly contributed to the company's growth and success.
Simon Tate's Role at Biogen
Following the acquisition of Convergence Pharmaceuticals by Biogen, Simon Tate took on the role of Vice President and Head of the Pain Therapeutic Area at Biogen. In this capacity, he continued his work in advancing research and development in the field of pain therapeutics.
Positions Held at GlaxoSmithKline (GSK)
Before his tenure at Convergence Pharmaceuticals, Simon Tate spent 20 years at GlaxoSmithKline (GSK). He held various senior roles, including Vice President and Head of Pain, Epilepsy, and Migraine drug discovery and early development. Additionally, he worked in Neurology, Psychiatry, and Discovery Sciences, where he contributed to significant advancements in these fields.